Clinical application of RUBCN/SESN2 mediated inhibition of autophagy as biomarkers of diabetic kidney disease

Table 5 ROC curve analysis of serum RUBCN, SESN2, mTOR, and RUBCN and SESN2 expression as biomarkers of early nephropathy

Test Result Variable(s)	ROC_AUC (95% CI)	Cutoff	Sensitivity (%)	Specificity (%)	Std. Error	Asymptotic Sig
Serum RUBCN (ng/mL)	1	> 2	100	98	0.000	< 0.001*
Serum SESN2 (ng/mL)	0.995 (0.985–1)	< 6.15	96.7	68.5	0.047	< 0.001*
Serum mTOR (ng/mL)	0.937 (0.881–0.993)	> 3.05	83.3	84.3	0.029	< 0.001*
Relative RUBCN expression	1	> 3.4	100	100	0.000	< 0.001*
Relative SESN2 expression	0.969 (0.935–1)	< 0.65	98	83.3	0.017	< 0.001*

^*Indicates statistical significance (P < 0.05); All calculated P were < 0.001
ROC: receiver operating characteristics; AUC: area under the curve; CI: confidence interval; RUBCN: Rubicon; SESN2: Sestrin-2; mTOR: mammalian target of rapamycin
Receiver operating curve was constructed using patients test results. The cutoff point was selected to be the closest to the upper left corner of the curve to achieve the highest sensitivity and specificity

ISSN: 1528-3658